Published in Oncoimmunology on September 09, 2016
Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment. Oncoimmunology (2017) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Cancer immunotherapy comes of age. Nature (2011) 12.35
Taking dendritic cells into medicine. Nature (2007) 11.82
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol (2005) 6.57
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol (2008) 5.35
Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 5.07
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 4.65
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res (2010) 3.57
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29
Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat Cell Biol (2010) 2.55
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab (2012) 2.48
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood (1999) 2.47
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol (2004) 2.12
miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood (2011) 1.73
miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity (2014) 1.70
miR-155: an ancient regulator of the immune system. Immunol Rev (2013) 1.68
Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol (2005) 1.67
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ (2007) 1.35
Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol (2009) 1.28
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A (2014) 1.22
Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood (2011) 1.16
Dendritic cells and cancer immunotherapy. Curr Opin Immunol (2014) 1.11
IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol (2008) 1.11
Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol (2011) 1.02
Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. Hum Immunol (2010) 1.01
MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer (2014) 0.99
Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer. PLoS One (2012) 0.98
miR-155-deficient bone marrow promotes tumor metastasis. Mol Cancer Res (2013) 0.98
Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release (2013) 0.94
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res (2016) 0.91
Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat (2014) 0.91
Sustained enhanced growth of carcinoma EO771 in C57 black mice. Proc Soc Exp Biol Med (1951) 0.89
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. Front Med (2011) 0.88
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A (2014) 0.87
Repression of arginase-2 expression in dendritic cells by microRNA-155 is critical for promoting T cell proliferation. J Immunol (2014) 0.87
Epigenetic control of Ccr7 expression in distinct lineages of lung dendritic cells. J Immunol (2014) 0.78
miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1. J Immunol (2015) 0.77